Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

Eugènia Negredo; Anna Bonjoch; Roger Paredes; Jordi Puig; Bonaventura Clotet

doi:10.1086/432879

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

Eugènia Negredo, Anna Bonjoch, Roger Paredes, Jordi Puig, Bonaventura Clotet

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

23 Cites (Scopus)

Resum

The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. © 2005 by the Infectious Diseases Society of America. All rights reserved.

Idioma original	Anglès
Pàgines (de-a)	901-905
Revista	Clinical Infectious Diseases
Volum	41
DOIs	https://doi.org/10.1086/432879
Estat de la publicació	Publicada - 15 de set. 2005

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1086/432879

Altres arxius i enllaços

https://www.scopus.com/pages/publications/24644466668

Com citar-ho

@article{bd22c71e04ef4e7db6b70adc3917da9b,

title = "Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies",

abstract = "The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. {\textcopyright} 2005 by the Infectious Diseases Society of America. All rights reserved.",

author = "Eug{\`e}nia Negredo and Anna Bonjoch and Roger Paredes and Jordi Puig and Bonaventura Clotet",

year = "2005",

month = sep,

day = "15",

doi = "10.1086/432879",

language = "English",

volume = "41",

pages = "901--905",

}

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. / Negredo, Eugènia; Bonjoch, Anna; Paredes, Roger et al.
In: Clinical Infectious Diseases, Vol. 41, 15.09.2005, pàg. 901-905.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

AU - Negredo, Eugènia

AU - Bonjoch, Anna

AU - Paredes, Roger

AU - Puig, Jordi

AU - Clotet, Bonaventura

PY - 2005/9/15

Y1 - 2005/9/15

N2 - The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. © 2005 by the Infectious Diseases Society of America. All rights reserved.

AB - The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. © 2005 by the Infectious Diseases Society of America. All rights reserved.

UR - https://www.scopus.com/pages/publications/24644466668

U2 - 10.1086/432879

DO - 10.1086/432879

M3 - Article

SN - 1058-4838

VL - 41

SP - 901

EP - 905

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho